Red light therapy for skin cancer

What the Science Says: PBM, Skin Cancer, and Oncological Safety

The first question on everyone's mind is direct: Can red light therapy cause or worsen skin cancer? Unlike UV light — a proven carcinogen — red and near-infrared light are non-ionising and do not damage DNA. The American Academy of Dermatology confirms that red light therapy does not carry the cancer risk associated with UV exposure. This is a foundational distinction: the sun that burns and damages is ultraviolet; the light used in photobiomodulation is in the 600–1000nm range, entirely outside the UV spectrum.

A landmark 2023 systematic review in the Aesthetic Surgery Journal (PMC10309024) analysed 57 papers including 41 in vitro studies, 9 in vivo studies, and 7 clinical trials. Its conclusion was clear: "There is no evidence to support the proposition that PBM should be avoided by patients who have previously undergone treatment for cancer." Within established therapeutic parameters, PBM mainly enhances healthy cell proliferation while showing a tendency to reduce or not influence neoplastic cell viability — the opposite of the theoretical concern.

A complementary preclinical study (PMC3423866) tested 670nm red light therapy daily on mice with UV-induced squamous cell carcinoma tumours over 37 days. The result: no measurable effect on tumour growth at therapeutic parameters. The treated mice also showed visibly healthier skin tissue and improved systemic behaviour compared to controls — a finding consistent with PBM's well-established anti-inflammatory and tissue-repair mechanisms.

How PBM Works — and Why It's Different from UV or PDT

Think of photobiomodulation like sunlight fuelling photosynthesis in a plant — except here, specific red and near-infrared wavelengths fuel your cells' own mitochondria. When red (660nm) or near-infrared (850nm) photons reach skin tissue, they are absorbed by cytochrome c oxidase, a key enzyme in the mitochondrial energy chain. This triggers increased ATP production, reduced oxidative stress, nitric oxide release, and a cascade of anti-inflammatory and regenerative signals. The result in healthy tissue: faster repair, improved circulation, collagen stimulation, and reduced inflammation.

It is equally important to distinguish PBM from photodynamic therapy (PDT). PDT is an established dermatological treatment for actinic keratosis and certain non-melanoma skin cancers — it uses photosensitising agents activated by light to destroy abnormal cells. PBM involves no drugs and no ablative mechanism. Confusing them is understandable but misleading. RedLightLux devices use PBM exclusively — not PDT.

Red Light Therapy with a Skin Cancer History: Where It May Help

For people cleared by their dermatologist after treatment for non-melanoma skin cancers or early-stage melanoma, photobiomodulation offers meaningful wellness applications — particularly for the skin damage that treatment itself leaves behind. Here is where the evidence is strongest.

1. Post-Surgical Wound Healing After Skin Cancer Excision

Surgical excision is the most common treatment for basal cell and squamous cell carcinoma. A 2026 PMC study on near-infrared light and post-surgical wound healing confirmed that NIR photobiomodulation is associated with faster healing and reduced postoperative pain. PBM stimulates fibroblast activity and collagen synthesis, supporting the skin's natural repair process — relevant for those left with post-excision scarring or slow-healing tissue.

2. Sun Damage and Photoaging Repair

Most people with a skin cancer history have significant cumulative sun damage — the same UV-induced photoaging that elevates skin cancer risk also produces fine lines, pigmentation, and impaired skin barrier function. Red light therapy for sun damage is one of PBM's most evidence-rich applications. 660nm light stimulates collagen production, accelerates keratinocyte repair, and reduces chronic skin inflammation — supporting overall skin health, skin tone, and resilience in photodamaged skin.

3. Radiation Dermatitis from Radiotherapy

Some skin cancer patients receive adjuvant radiotherapy. Radiation dermatitis — painful, inflamed, slow-healing skin — affects the majority of those treated. A 2026 clinical trial on LED-based PBM for radiodermatitis in breast cancer (using comparable protocols) adds to a growing body of evidence that 660nm and 850nm PBM reduces radiation-induced skin inflammation and accelerates tissue repair. These findings are relevant for skin cancer patients who have undergone radiation.

Safety Rules and Contraindications for Skin Cancer Patients

Key Safety Principles

• Never apply over active, suspected, or unexcised lesions

  This is the most critical rule. Regardless of what the science suggests about PBM at therapeutic parameters, applying any device over an unconfirmed or untreated lesion is contraindicated. Full medical clearance of any suspicious site must come first.

• Obtain dermatologist clearance — even after successful treatment

  Being cleared of skin cancer does not automatically mean unrestricted PBM use. Your dermatologist can assess your specific cancer type, treatment history, and current skin status to advise on appropriateness, session duration, and areas to avoid.

• Photosensitising medications require special attention

  Some skin treatments — including certain topical chemotherapy agents or medications for actinic keratosis — can increase photosensitivity. If you are using such treatments, discuss light therapy with your prescribing doctor before starting any PBM protocol.

• Use only certified, low-EMF, flicker-free LED devices

  Device quality is non-negotiable for anyone with a skin health concern. All RedLightLux panels — from the compact Micro to the full-body Ultimate Panel — are CE/FCC/RoHS/SAA/ARTG certified, zero EMF, and lab-tested for a minimum of six months before launch. This level of verified quality matters when skin health is a priority.

• Monitor your skin and attend all follow-up appointments

  Red light therapy does not replace your regular dermatology screenings. Continued vigilance — annual or biannual skin checks — is the cornerstone of skin cancer survivorship, independent of any wellness protocol you adopt.

Choosing the Right Device: Quality, Wavelength, and Protocol

If your dermatologist has cleared you for red light therapy, selecting the right device is the next critical decision. For those with a skin health history, quality and certification are non-negotiable. Here is what to prioritise.

Wavelength Selection

For skin-focused goals — sun damage repair, collagen production, post-surgical healing, and radiation dermatitis — 660nm red light is your primary tool. It targets the surface layers of the skin, stimulating fibroblasts, boosting collagen synthesis, and reducing inflammation. For deeper tissue recovery — post-operative healing or inflammation beneath the skin — pairing with 850nm near-infrared light provides greater penetration depth. All RedLightLux dual-wavelength panels deliver both 660nm and 850nm simultaneously, validated across dermatological and photobiomodulation applications.

Protocol Guidance

For those with a skin cancer history starting PBM under dermatologist guidance: begin with shorter sessions (5–10 minutes), at a conservative distance (20–30cm from the panel), 3–4 times per week. Avoid previously treated or monitored sites. Gradually increase session duration as tolerated, in line with your clinician's guidance. Never exceed 20 minutes per area in a single session with consumer-grade panels.

"For those with a skin cancer history, the question is not simply 'is red light therapy safe?' — it's 'is it safe for me, for my specific sites, with my dermatologist's knowledge?' That distinction is everything."

The RedLightLux Portable Panel is the ideal starting point for those in post-treatment recovery. It offers targeted, manageable sessions and the flexibility to treat specific areas — away from any monitored sites — with precision. For broader skin health support during remission, the Max Panel delivers high-irradiance dual-wavelength coverage. All devices are lab-tested for a minimum of six months, backed by a one-year manufacturer's warranty, and certified to CE/FCC/RoHS/SAA/ARTG standards.

Conclusion: Informed Decisions, Science-Grounded Wellness

The relationship between red light therapy for skin cancer is nuanced but navigable. Three evidence-based conclusions are clear. First, red and near-infrared light are non-ionising and do not cause DNA damage — they are biologically distinct from the UV radiation that causes skin cancer. Second, the current systematic evidence base finds no documented promotion of skin tumour growth at therapeutic PBM parameters, and identifies meaningful post-treatment wellness applications in wound healing, sun damage repair, and radiation dermatitis management. Third, for anyone with a skin cancer history, dermatologist clearance, avoidance of active or monitored lesion sites, and the use of certified, quality-verified devices are the non-negotiable foundation of safe practice.

At RedLightLux, Arnaud and Olha have built a platform on total transparency — offering CE/FCC/RoHS/SAA/ARTG certified devices from the compact Micro (€118) to the full-body Ultimate (€2,278), all lab-tested for six months minimum. For those navigating skin health after cancer, this standard of device quality is not a luxury — it is the baseline. Explore the RedLightLux range and take the next step in evidence-informed, skin-first wellness — with your healthcare team's guidance.

Frequently Asked Questions — Red Light Therapy and Skin Cancer